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IS THERE A ROLE FOR THE PHARMACIST IN 
SCREENING FOR METABOLIC SYNDROME? 
Background:
Evidence for a pharmacist role in the screening of MetS has been shown to be effective in at-risk populations (1). Despite, migrants being an 
at-risk group for the development of MetS, no literature has described screening of migrants by pharmacists.  
Aim:
To identify the impact, of the pharmacist role in screening migrants upon arrival in a Middle Eastern country and following 24 months of 
residency in the Middle East (ME) .
Methods:
❖ This prospective longitudinal observational study is being conducted over two periods. The initial phase was the retrospective pharmacist 
facilitated screening process of the migrants to Qatar (the new HMC employees, within three months of arrival to Qatar) included screening for 
DM, HTN, central obesity and dyslipidemia (high triglycerides and low high density cholesterol). Migrants with normal metabolic parameters at 
baseline were included in the second phase which is the follow-up study 24 months post residing in Qatar, as illustrated in figure 1. Follow-up 
laboratory tests, BP and waist circumference measurement are being repeated two years post residing in Qatar. Moreover, a questionnaire to 
address the change in their lifestyle since migration is being applied (Figure 2).
❖ Participants were coded with a unique study identification number on data collection sheets and during data analysis
❖ Descriptive analysis was utilized for baseline characteristics. ANOVA test will be applied to ascertain the incidence of the new MetS-
development after exposure to migration. 
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Figure 4 – The potential impact of  the project Figure 3– The recruitment process 
Figure 2 : Flow diagram of  participant follow up during period two 
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Each participant was interviewed to undertake the WHO 
STEPwise questionnaire (3) and had parameters measured: 
FBG, TG and HDL-C and BP & waist circumference 
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Conclusion
The study indicates that pharmacist screening is 
effective for early identification and potential early 
management of  MetS in this migrant population. 
The findings of  this study will contribute to the evidence 
about the relation between migration to Qatar and MetS
development. Findings will also inform HMC policies about 
the risk and incidence of  MetS amongst migrants residing in 
Qatar. 
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